R&D/Clinical Trials

Novo Nordisk presented the findings at the AASLD 76th annual meeting.

Recent research shows mRNA COVID vaccines significantly enhance survival rates in cancer patients undergoing immunotherapy, potentially revolutionizing cancer treatment.

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, emphasizing the balance between cost, risk, and speed in advancing laminin-based technologies that could accelerate next-generation cell and gene therapies.

Acadia Pharmaceuticals’ CEO Catherine Owen Adams discusses the current climate in R&D and details her leadership style.

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

The company did not provide a reason for the bimagrum trial’s halting.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent clinical trials.

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos, developed using the company’s AdenoVerse platform, became the first FDA-approved therapy for adult patients with recurrent respiratory papillomatosi.

Marc Stapley, CEO of Veracyte, reviews upcoming developments in the diagnostic space.

Sanofi's stock plummets over 10% as Amlitelimab's Phase III trial results raise concerns about the company's future pipeline and Dupixent's patent expiration.

The OSE Immunotherapeutics CEO discusses recent develops with this potentially game-changing space in oncology.

Marc Stapley, CEO of Veracyte, discusses the importance of ongoing evidence collection.

Marc Stapley, CEO of Veracyte, discusses new approaches to diagnostics and how its transforming cancer care.

Are we letting momentum outpace readiness?

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives steering innovative scientific and strategic pursuits in R&D, market access, and patient support.

A mission leader in next-generation pursuits around targeted therapy.

Pioneer of cell-reset technology steers science-to-startup transformation.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains committed to future treatments.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with promising RNA interference programs.

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab significantly reduces disease activity and shows a favorable safety profile in adults with active Sjögren’s disease.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease trial data.

Results from the Phase III CONVOKE trial (NCT05838625) showed that CT-155 demonstrated a favorable safety profile consistent with previous studies in patients with schizophrenia.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.